UCB (ENXTBR:UCB) has put generalized myasthenia gravis back in focus after showcasing an extensive data package on zilucoplan, rozanolixizumab and investigational T cell engager cizutamig at the AANEM and MGFA meetings in Orlando.
Investors have been reassessing UCB through a busy September schedule of medical conferences and investor calls, with the latest share price at €202.3 after a 1-day share price return of 0.7% and a 90-day share price return that has fallen 18.7%. Even so, the 3-year total shareholder return is up about 160%, which indicates that long-term holders remain significantly ahead despite recent momentum fading in the short term.
Compare UCB's neurology and immunology focus with a hand-picked 126 healthcare AI stocks that are also trying to reshape complex disease treatment through data and precision medicine.
After a near 19% slide over 90 days, UCB now trades around €202 while average analyst targets cluster closer to €285. Is that gap a valuation trap or a genuine mispricing that the numbers explain?
Most Popular Narrative: 11% Undervalued
On the most followed narrative, UCB screens as undervalued, with a fair value of €227.49 against the current €202.3 share price. This puts the focus squarely on how that estimate is built.
The fair value shown on this page is a discounted cash flow, because that's what this platform's format is built on. My full method at StoxEurope ran five models on UCB. Two independent ones, the DCF and a free-cash-flow-to-equity model, corroborated within a 6,8 % band, and the platform published a consolidated estimate of 227,49 euro, band 227,49 to 243,49. The 243,49 in the field above is the top of that band, not the conclusion. The published estimate is the panel's median, which is the FCFE figure.
See why 2 investors see UCB as 11% undervalued.
Result: Fair Value of €227.49 (UNDERVALUED)
Still, the fair value story for UCB can crack if discount rate assumptions prove too low or if key neurology and immunology franchises underperform expectations.
Find out about the key risks to this UCB narrative.
Next Steps
If the mixed sentiment around UCB leaves you unconvinced, shift from opinions to evidence and test the thesis against the data yourself using the 5 key rewards.
Looking for more UCB-sized ideas?
If UCB has sharpened your appetite for opportunity, do not stop here. Use these focused screens to pressure test your next moves before the crowd notices.
- Target value first by scanning companies that combine earnings quality with discounted pricing through the 185 high quality undervalued stocks.
- Prioritise resilience by filtering for businesses with strong finances and clean balance sheets using the list of solid balance sheet and fundamentals (206 results).
- Hunt for under-the-radar potential by checking the 614 high quality undiscovered gems before others catch on.
This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.
Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team@simplywallst.com